会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods and compositions involving immunostimulatory oligodeoxynucleotides
    • 涉及免疫刺激性寡脱氧核苷酸的方法和组合物
    • US08568742B2
    • 2013-10-29
    • US10297555
    • 2001-06-07
    • Walter SchmidtKaren LingnauCarola SchellackAlena Egyed
    • Walter SchmidtKaren LingnauCarola SchellackAlena Egyed
    • A61K47/00A61K45/00A61K39/00A61K48/00C12N15/11C07H21/02
    • A61K39/39A61K31/7088A61K38/00A61K39/00A61K39/0011A61K2039/55516A61K2039/55561C07H19/24C07H21/00C12N15/117C12N2310/18C12N2310/315C12N2310/33Y02A50/412
    • Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
    • 描述了具有式(I)结构的免疫刺激性寡脱氧核酸酸分子(ODN),其中任何NMP是选自脱氧腺苷,脱氧鸟苷,脱氧肌氨酸,脱氧胞嘧啶,脱氧尿苷的2'脱氧核苷单磷酸或一硫代磷酸酯 - 脱氧胸苷,2-甲基 - 脱氧肌苷,5-甲基 - 脱氧胞嘧啶,脱氧伪嘌呤,脱氧核糖嘌呤,2-氨基 - 脱氧核糖嘌呤,-6-S-脱氧鸟嘌呤,2-二甲基 - 脱氧鸟苷或N-异戊烯基 脱氧腺苷 - 脱氧腺苷,脱氧胸苷,2-甲基 - 脱氧肌苷,5-甲基 - 脱氧肌苷,脱氧腺苷,脱氧腺苷,脱氧肌苷, 脱氧胞嘧啶,脱氧嘌呤,脱氧核糖嘌呤,2-氨基 - 脱氧核糖嘌呤,6-S-脱氧鸟嘌呤,2-二甲基 - 脱氧鸟苷或N-异戊烯基 - 脱氧腺苷,任何X是O或S,a和b是0 到100,附带条件是a + b在4至150之间,B和E是核酸分子的5'或3'末端的常见基团,以及含有这种ODN的药物组合物。
    • 6. 发明授权
    • Immunostimulatory oligodeoxynucleic molecules
    • 免疫刺激性寡脱氧核糖分子
    • US07858588B2
    • 2010-12-28
    • US10478771
    • 2002-05-17
    • Karen LingnauCarola SchellackWalter Schmidt
    • Karen LingnauCarola SchellackWalter Schmidt
    • A01N31/70A61K39/00A61K45/00C12N5/00
    • C12N15/117A61K2039/55561C12N2310/18C12N2310/315C12N2310/33
    • Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any X is O or S, any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
    • 描述了具有式(I)结构的免疫刺激性寡脱氧核酸分子(ODN),其中任何X是O或S,任何NMP是2'-脱氧核苷单磷酸或一硫代磷酸酯,其选自脱氧腺苷,脱氧鸟苷 - ,脱氧肌苷,脱氧胞嘧啶,脱氧尿苷,脱氧胸苷,2-甲基脱氧肌苷,5-甲基脱氧胞嘧啶,脱氧嘌呤,脱氧核糖嘌呤,2-氨基 - 脱氧核糖嘌呤,-6-S-脱氧鸟嘌呤, 二甲基脱氧鸟苷或N-异戊烯基 - 脱氧腺苷一磷酸或一硫代磷酸酯,NUC是2'-脱氧核苷,选自脱氧腺苷,脱氧鸟苷,脱氧肌苷,脱氧胞嘧啶,脱氧尿苷,脱氧胸苷,2-甲基 脱氧肌氨酸 - ,5-甲基 - 脱氧胞嘧啶 - ,脱氧伪嘌呤 - ,脱氧核糖嘌呤 - ,2-氨基 - 脱氧核糖嘌呤 - ,6-S-脱氧鸟嘌呤 - ,2-二甲基 - 脱氧鸟苷或N-异戊烯基 - 脱氧腺苷,任何X是O或S ,a和b整数从0到100与t 他的条件是a + b在4到150之间,B和E是核酸分子的5'或3'末端的常见基团,以及含有这种ODN的药物组合物。